Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Freemantle, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freemantle, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 232-234
© 2000 British Society for Rheumatology

Editorials

Cost-effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs)—what makes a NSAID good value for money?

N. Freemantle

Medicines Evaluation Group, Centre for Health Economics, University of York, UK.

Family practitioners in England prescribe about 1.5 million person years of non-steroidal anti-inflammatory drugs (NSAIDs) [1]. Most treatment is for the relief of pain in patients with osteoarthritis managed in primary care, although often these patients do not formally gain a diagnosis, their symptoms being managed pragmatically. NSAIDs are also widely used in the long-term management of patients with rheumatoid arthritis, but the volume of use for these patients is considerably less. There is good evidence that, in the management of pain, NSAIDs have some advantages over simple analgesics such as paracetamol (acetaminophen). However, these advantages are associated with an increase in the risk of serious gastrointestinal episodes [1].

The problems associated with traditional NSAIDs have fostered pharmacological research aiming to discover the mode of action leading to gastrointestinal events [2, 3] and to identify new agents which achieve the benefits of traditional . . . [Full Text of this Article]

Declaration of conflict of interest

Acknowledgments

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
N. J. Cooper, M. Mugford, D. P. M. Symmons, E. M. Barrett, and D. G. I. Scott
Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study
Rheumatology, July 1, 2002; 41(7): 767 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. S. M. Jawad
Re: NSAIDS and simple analgesics
Rheumatology, August 1, 2001; 40(8): 945 - 945.
[Full Text] [PDF]